T esting donated blood for viral nucleic acids should reduce the residual risk of virus transmission by detecting donations made during the preseroconversion window period. 1 Because current nucleic acid amplification technologies do not have sufficient throughput for testing individual units at a reasonable cost, testing of mini-pools made up of small aliquots from many individual units has been proposed.
1-3 Several studies have shown that mini-pool testing can be incorporated into existing blood donor screening programs and that it should be able to detect window-period donations. [4] [5] [6] [7] One such study demonstrated the feasibility of screening mini-pools by PCR for HCV, HBV, and HIV-1. 7 An inhouse PCR assay identified 7 HIV-1-positive donations out of 373,423 donations tested (as 4,500 mini-pools). None of these 7 represented window-period donations, because they were also positive in the standard serologic test. PCR did not miss any known infections, as the remaining 373,416 donations were also negative in the standard serologic test. The frequency of false-positive results was, however, somewhat high; approximately 2 percent of minipools yielded positive results that were not confirmed during retesting. At least a portion of this difference was attributed to limitations of the in-house assay. In this study, HCV was detected by a commercial test (COBAS AMPLICOR HCV Test, Roche Molecular Systems, Somerville, NJ). The number of HCV-false-positive results was approximately one-fifth the number of HIV-1-(and HBV-)false-positive results. 7 After modification of the amplification conditions, the specificity of the in-house HIV-1 test approached that of the COBAS AMPLICOR HCV test. 7 Ready to use, quality-controlled, commercial PCR tests should be used for mini-pool testing to spare blood and plasma centers the need to devote inordinate resources to the design, manufacture, validation, and QC of their own reagents and methods. As the above study suggests, commercial assays are also likely to be more specific, thereby improving productivity by minimizing the number of falsepositive results that have to be resolved by costly pool breakdown testing.
An in vitro nucleic acid amplification test for the qualitative detection of HIV-1 RNA in plasma (COBAS AmpliScreen HIV-1 test, Version 1.5 [v1.5], Roche) was designed for screening pools of donated human plasma that have been pooled according to approved algorithms. The HIV-1-positive sample(s) in the pool are identified by sequential testing of secondary pools and then of the individual units within secondary pools that test positive. The test utilizes the same primers and probe as the quantitative COBAS AMPLICOR HIV-1 MONITOR test (Roche). Primary plasma pools composed of 24 units and secondary pools composed of 6 units are prepared by a specimen-processing procedure (Multiprep, Roche) that simultaneously extracts and concentrates HIV-1, HCV, and HBV particles from plasma. 8 Individual samples are prepared by the standard specimen-processing procedure that does not incorporate a sample concentration step. Amplification, detection, and the reporting of results are automatically performed by the COBAS AMPLICOR analyzer without user intervention.
The objective of this study was to demonstrate that the COBAS AmpliScreen HIV-1 test, v1.5, meets the performance specifications for screening donated plasma pools. We determined the limit of detection, evaluated the analytical and clinical specificity, and tested various substances for their ability to interfere with the test. We also assessed test reactivity with all HIV-1 group M subtypes and determined whether the test could detect HIV-1 before seroconversion and before the appearance of p24 antigen (p24Ag) in wellcharacterized seroconversion panels. Finally, we determined whether the test could accurately detect positive pools and correctly identify the infected unit within those pools.
MATERIALS AND METHODS

Specimens
A 30-member subtype panel (Walter Reed Army Institute of Research and the Henry M. Jackson Foundation, Rockville, MD) was used to evaluate test reactivity and the limit of detection with various HIV-1 group M subtypes. Each of the 30 panel members was cultured, and the virus particle concentration in the culture supernatant was determined by electron microscopy. In addition, analytical sensitivity was assessed by using the HIV-1 Working Standard (97/632), which was obtained from the National Institute for Biological Standards and Controls (NIBSC, Potters Bar, UK).
To assess clinical specificity, blood samples from 500 and 513 blood donors who were negative for all of the required infectious disease markers were collected, respectively, from the Sacramento Blood Center (SBC, Sacramento, CA) and the Gulf Coast Regional Blood Center (GCRBC, Houston, TX). The HIV-1-positive clinical specimens used for assessing test reproducibility were EDTA plasma specimens obtained from BioQual International (Plainville, MA). BioClinical Partners (Franklin, MA) provided blood samples from seropositive and seronegative donors for interference studies.
BioClinical Partners provided HIV-1 seroconversion panels that had been characterized with licensed HIV-1 antibody and HIV-1 p24Ag tests. We defined the date of anti-HIV-1 seroconversion as the day on which the anti-HIV-1 test yielded a positive result.
Specificity testing
With the exception of the HCV and HBV samples and one bacterial isolate, all samples were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The HCV samples were obtained from Millennium Biotech (Miami, FL), and the viral concentrations were determined with the COBAS AMPLICOR HCV MONITOR test, version 2.0. The HBV samples were obtained from SBC and the viral concentrations were determined by an in-house quantitative method at Roche Molecular Systems (Pleasanton, CA). The Staphylococcus epidermis bacterial isolate was provided by the Roche Molecular Systems Culture Collection Group (Alameda, CA).
Plasma-pooling procedure
A robotic pipettor (MicroLab AT/Plus 2, Hamilton, Reno, NV) combined aliquots of 24 individual plasma samples to create primary pools. During the preparation of the primary pools, the pipettor also transferred 1.5 mL of each plasma sample from the collection tube to an archive plate, where each sample was stored for up to 7 days for possible further testing. If the primary pool tested positive, the pipettor prepared four secondary pools, each comprising 6 plasma samples, from the aliquots of the 24 plasma samples stored in the archive plate. If a secondary pool tested positive, the pipettor transferred 200 µL of each of the 6 plasma samples in the pool from the archive plate to a sample processing tube for individual sample testing.
Specimen preparation
Multiprep method. The Multiprep method has been described previously. 8 Briefly, virus particles were concentrated from 1 mL of plasma by centrifugation. The resulting pellet, together with 100 µL of the supernatant, was treated with working lysis buffer (AmpliScreen Lysis Buffer, Roche), containing internal control (IC) RNA molecules at a concentration equivalent to 20 copies per amplification reaction, to lyse the viral particles. The released viral nucleic acid was precipitated with isopropanol, washed with 1 mL of 70-percent ethanol, and resuspended in 200 µL of diluent (AmpliScreen Specimen Diluent, Roche). Fifty microliters of the processed sample, which contained nucleic acid recovered from 250 µL of plasma sample, was added to the amplification reaction.
Standard method. The Standard procedure was described previously, 8 at which time it was called the reference specimen-preparation procedure. 8 Briefly, viral nucleic acid was extracted by treating 200 µL of plasma with working AmpliScreen Lysis buffer. The released nucleic acid was precipitated with isopropanol, washed with 1 mL of 70-percent ethanol, and resuspended in 200 µL of AmpliScreen Specimen diluent. Fifty microliters of the processed sample, which contained nucleic acid recovered from 50 µL of plasma sample, was added to the amplification reaction.
Reverse transcription-amplification
The target sequence for the AmpliScreen HIV-1 test, v1.5, is a highly conserved region of the HIV-1 gag gene that encodes the group-specific antigens (core structural proteins) of the virion. 9 The Working AmpliScreen HIV-1, v1.5, Master Mix (Roche) is a bicine-buffered solution containing glycerol, potassium acetate, dNTPs (including dATP, dCTP, dGTP, dTTP, and dUTP), biotinylated primers (antisense primer SK431 and sense primer SK462), Thermus thermophilus DNA polymerase, AmpErase (uracil-nglycosylase), manganese acetate, and sodium azide. This reaction mixture supports both reverse transcription and DNA replication, which enables the entire amplification process to take place sequentially in a single tube. Processed samples were reverse-transcribed and amplified with the thermal cycler integrated in the COBAS AMPLICOR analyzer, which automatically performed the correct thermal-cycling program after the user entered the correct test name. One positive control and one negative control were amplified with each set of samples. These two controls and the IC do not undergo centrifugation and lysis and thus do not monitor the integrity of those processes.
Hybridization and detection
The two amplification products, 142-bp sequences generated from HIV-1 and IC target RNA, were detected colorimetrically after hybridization to HIV-1-specific and IC-specific oligonucleotide probes bound to magnetic particles. Upon completion of amplification, the COBAS AMPLICOR analyzer automatically denatured the reaction products, hybridized aliquots of denatured reaction products to the HIV-1-and IC-specific probes, detected the hybridized reaction products with an avidin-horseradish peroxidase conjugate and a substrate solution, measured the OD of the reaction at 660 nm with the spectrophotometer integrated in the COBAS AMPLICOR analyzer, and interpreted and printed the results.
RESULTS
Analytical sensitivity
The limit of detection was determined by performing endpoint titrations of the NIBSC HIV-1 Working Standard 97/ 632, which contained 40,000 copies per mL of HIV-1 RNA. The standard was serially diluted in HIV-1-negative plasma obtained from GCRBC (Experiment 1) or in three different plasma pools, each of which was constructed from 24 HIV-1-negative samples (Experiment 2). The samples diluted in the negative plasma were extracted by using both the Multiprep and Standard specimen-processing procedures; 24 replicate extractions were performed for each diluted sample, and a single amplification was performed for each extract. The samples diluted in pooled plasma were extracted by using the Multiprep specimen-processing procedure; eight replicate extractions were performed for each dilution in each of the three pools, for a total of 24 tests at each concentration. A test result was considered positive when the HIV-1 absorbance at 660 nm was >0.2.
With the Multiprep processing method, the test detected HIV-1 RNA in 100 percent of the replicates at concentrations equal to or greater than 25 copies per mL; 79 percent and 92 percent of the 24 replicates gave positive results at concentrations of 15 and 10 copies per mL, respectively (Table 1 ). We define the detection limit of the test as the concentration required to yield at least 95-percent positive results in a set of replicate reactions. Thus, when samples are processed by the Multiprep method, the limit of detection of the COBAS AmpliScreen HIV-1, v1.5, is 25 (or fewer) copies of HIV-1 RNA per mL of plasma measured with the NIBSC HIV-1 Working Standard 97/632.
With the Standard processing method, the test detected HIV-1 RNA in 96 percent and 100 percent of the rep- licates at concentrations of 100 and 200 copies per mL, respectively (Table 1) . The test detected 79 percent of replicates at a concentration of 75 copies per mL, and the detection rate fell further as the concentration decreased (Table 1) 
HIV-1 group M subtype reactivity
To verify that the test would achieve a similarly high level of sensitivity for all HIV-1 group M subtypes, we determined the limit of detection for each of 30 virus isolates. Each isolate was diluted to 50 virus particles per mL in normal human plasma, and 22 replicate aliquots were processed by the Multiprep specimenprocessing procedure; a single amplification-and-detection step was performed for each extracted sample. A test result was considered positive when the HIV-1 absorbance at 660 nm was >0.2. Most of those isolates that yielded >95-percent positive replicates at 50 particles per mL were also tested at lower concentrations. Those isolates that yielded <95-percent positive replicates at 50 particles per mL were tested at successively higher concentrations to identify the concentration that yielded >95-percent positive replicates.
With the Multiprep method, an analytical sensitivity of 20 to 75 particles per mL was achieved for 26 of the 30 isolates. The analytical sensitivity for the remaining 4 isolates, all of which were subtype E, was 100 to 200 particles per mL. Subtype A, B, C, D, F, and G isolates exhibited comparable limits of detection; a rate of >95-percent positive results was achieved at concentrations of 20 (2 isolates), 30 (6 isolates), 50 (8 isolates), and 75 (6 isolates) particles per mL (Table  2 ). Four of 8 subtype E isolates also had a limit of detection of 30 (2 isolates), 50 (1 isolate), or 75 (1 isolate) particles per mL, while the other 4 had detection limits of 100 (3 isolates) or 200 (1 isolate) particles per mL (Table 2) .
Consistent with the results obtained with the NIBSC HIV-1 Working Standard 97/632, the Standard method was also one-third to one-fifth as sensitive as the Multiprep method when tested on these viral isolates. The results obtained by the Standard method paralleled those obtained by the Multiprep method. An analytical sensitivity of 100 to 250 particles per mL was achieved for 26 of the 30 isolates. The analytical sensitivity for the remaining 4 isolates, all of which were subtype E, was 300 to 400 particles per mL. Subtype A, B, C, D, F, and G isolates exhibited comparable limits of detection; a rate of >95-percent positive results was achieved at concentrations of 100 (5 isolates), 150 (12 isolates), 200 (3 isolates), or 250 (2 isolates) particles per mL (data not shown). Four of 8 subtype E isolates also had a limit of detection of 200 (2 isolates) or 250 (2 isolates) particles per mL, while the remaining 4 had detection limits of 300 (1 isolate), 350 (2 isolates), or 400 (1 isolate) particles per mL (data not shown).
These results were confirmed by testing synthetic RNA transcripts prepared from DNA clones representing subtypes A, B, C, D, E, and G. The concentration of the transcript preparations was determined by an MuLV reverse transcriptase-cDNA plate assay. The transcripts were not prepared by the Multiprep or the Standard sample-preparation procedure. Instead, they were diluted into Multiprep Specimen diluent, and 24 aliquots (50-µL) of each dilution were directly amplified and detected by the standard COBAS AmpliScreen procedure. The dilutions tested were equivalent to 20, 10, 5, and 2 copies of transcript per amplification reaction. Subtypes A, B, C, D, and G yielded 96-or 100-percent positive results at a concentration of 5 copies per amplification reaction, whereas subtype E yielded 88-percent positive results. Subtype E yielded 100-percent positive results at a concentration of 10 copies per amplification reaction. All of the subtypes yielded less than 95-percent positive results (range, 50-88%) at a concentration of 2 copies per amplification reaction. Thus, the limit of detection was 5 copies per amplification reaction for subtypes A, B, C, D, and F and 10 copies per amplification reaction for subtype E.
These results are consistent with the limits of detection obtained with plasma samples prepared by the Multiprep and Standard procedures: 30 and 150 copies per mL, respectively. The equivalent of 250 or 50 µL of plasma, respectively, is added to each amplification reaction for samples processed by the Multiprep or Standard method. Thus, 7.5 copies are added to each amplification reaction when plasma containing 30 or 150 copies per mL is prepared by the Multiprep or Standard method, respectively.
Specificity
The analytical specificity of the AmpliScreen HIV-1 test, v1.5, was evaluated by testing a panel consisting of 36 microorganisms, including 31 viral isolates and 5 bacteria. The viruses tested included adenovirus types 2, 3, and 7; coxsackievirus B1; CMV; echovirus types 1 and 5; EBV; HAV; several HBV isolates; HCV isolates representing genotypes 1a, 1b, 2a/c, 2b, and 3a; herpes simplex virus types 1 and 2; human papillomavirus types 6, 16, and 18; HTLV-I; HTLV-II; and varicella-zoster virus. The bacterial isolates tested included Chlamydia trachomatis, Neisseria gonorrhoeae, Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis. Viral and bacterial isolates were added to negative human plasma from healthy donors, which was processed by the Multiprep sample-preparation procedure. The equivalent of 10 to 1000 µL of each stock suspension was processed, which resulted in testing of 790 to 8 × 10 8 median tissue culture-infective dose units or copies per amplification reaction. When detected with the HIV-1-specific probe, all isolates tested produced negative results that were well below the test cutoff (data not shown). The negative results for HIV-1 were not caused by inhibition, as all IC signals were positive (data not shown). These results demonstrate that the test is specific for HIV-1 and will not generate false-positive signals should donated blood contain any of the infectious agents tested.
The clinical specificity of the test was evaluated by testing individual blood donations that were seronegative in FDA-licensed anti-HIV-1 tests. Sets of 500 and 513 samples were prepared by the Multiprep and Standard methods, respectively. All prepared samples were amplified and detected on the COBAS AMPLICOR analyzer by the standard test procedure. For both sample-preparation methods, all of the samples gave negative results for HIV-1 using a cutoff of A 660 0.2 (data not shown). These negative results were valid, because all 1013 samples yielded positive IC results (data not shown).
Reproducibility
The reproducibility of the COBAS AmpliScreen HIV-1 test, v1.5, was evaluated in a multisite study conducted at Roche Molecular Systems, SBC, and Memorial Blood Centers (Minneapolis, MN). A panel of 10 samples was tested: 6 clinical samples with concentrations ranging from 600 to 200,000 copies per mL (as determined by the COBAS AMPLICOR HIV-1 MONITOR test, v1.5); two dilutions of the NIBSC Standard 97/632 made in negative human plasma to 100 and 300 copies per mL for the Multiprep method and 300 to 600 copies per mL for the Standard method; and two controls, the AmpliScreen HIV-1 Positive Control, v1.5, and the AmpliScreen Multiprep Negative Control. At each of the three sites, each member of the panel was tested by each of two operators on each of 2 days; the operators did not know the composition of the panel. Each sample was prepared and tested in duplicate each time the panel was tested, for a total of 24 results for each panel member. This evaluation was conducted for samples prepared by both the Multiprep and Standard sample-processing procedures. Reproducibility was determined qualitatively as the number of correct (positive or negative) results obtained. A test result was considered positive when the HIV-1 A 660 was >0.2.
Each operator correctly reported the expected qualitative test result for each panel specimen, for a total of 100-percent (24/24) correct results for each of the 10 samples in the test panel (Table 3 ). The negative sample and each positive sample always gave results that were, respectively, at least A 660 0.16 below and A 660 1.2 above the A 660 0.2 cutoff (Table 3) . Thus, the COBAS AmpliScreen HIV-1 test, v1.5, exhibited excellent reproducibility for both the Multiprep www.transfusion.org and Standard sample-preparation methods when negative and low-, moderate-, and high-titer HIV-1 RNA samples were tested together.
Interference studies
To determine whether endogenous substances interfere with the test, blood samples containing elevated albumin, bilirubin, Hb, or triglycerides were compared to blood samples containing normal levels of those components. A small quantity of NIBSC HIV-1 Working Standard 96/810 was added to each sample to achieve a final concentration of approximately 100 copies per mL. The samples were processed by either the Multiprep or the Standard specimenpreparation method and tested. For each preparation method, all 40 samples with an elevated plasma component yielded strongly positive HIV-1 signals, similar to those obtained for the normal human plasma controls (Table 4 ). Samples containing an elevated plasma component gave negative results for HIV-1 when tested without the NIBSC HIV-1 standard (data not shown).
Detection of HIV-1 RNA in seroconversion panels
Ten seroconversion panels were analyzed to show that the COBAS AmpliScreen HIV-1 test, v1.5, could detect HIV-1 before p24Ag becomes detectable and thus could substantially reduce the window period between infection and anti-HIV-1 seroconversion. The panel members were tested by the Multiprep processing method. Before sample preparation, panel members were diluted 1-in-24 with HIV-1-negative plasma to mimic the results that would have been obtained had they been tested by pooling. The undiluted panel members were also tested for HIV-1 p24Ag. The operator did not know the composition of the panels.
The COBAS AmpliScreen test detected HIV-1 RNA 2 to 14 days before anti-HIV-1 seroconversion in each of the 10 panels (Table 5 ). The p24Ag test also detected HIV-1 infection before anti-HIV-1 seroconversion in 9 of the 10 panels; p24Ag became positive 18 days after anti-HIV-1 seroconversion in the remaining panel (Table 5) . The COBAS AmpliScreen test detected HIV-1 RNA 3 to 28 days earlier than did the p24Ag test in 5 of the 10 panels (Table 5 ). In 5 of the 10 panels, the Standard method de- (1.747-4.000) * For both the Multiprep and Standard sample-preparation procedures, each sample was tested four times by each of two operators at each of three sites for a total of 24 tests. † Titer for the HIV-1 (+) control is expressed in copies per amplification reaction. For all other samples, the titer is expressed in copies per mL. ‡ The number of replicate tests that gave negative results (A 660 <0.2) for the negative control or positive results (A 660 >0.2) for the HIV-1-positive samples.
tected HIV-1 RNA 2 to 7 days earlier than did the Multiprep method (Table 5 ). This is not unexpected, as the fivefold concentration achieved by the Multiprep method only partially compensates for the 1-in-24 dilution during pooling.
Detection of positive pools and identification of positive units within pools
A validation study was conducted to show that the COBAS AmpliScreen HIV-1 test, v1.5, can detect pools containing a positive unit and can correctly identify the positive unit. Twenty sets of samples, each consisting of 24 plasma samples, were evaluated by each of three operators, who did not know the composition of the samples. In 10 of the sets, all 24 plasma samples were negative for HIV-1 RNA. The other 10 sets contained 1 HIV-1-positive plasma sample and 23 HIV-1 RNA-negative plasma samples; the positive sample contained 2,400 copies per mL in 5 sets and 1,000,000 copies per mL in the other 5. The position of the HIV-1-positive sample in each set for each operator was randomly chosen and was not known to the operator. Each operator tested 4 sets of samples on each of 5 days. The individual samples in each set were taken through the pooling process to create primary testing pools composed of 24 plasma samples (see Materials and Methods). The primary pools were prepared by the Multiprep method and tested by the COBAS AmpliScreen HIV-1 test, v1.5. For those primary pools that tested positive, four secondary pools, containing Samples 1 to 6, 7 to 12, 13 to 18, and 19 to 24, respectively, were prepared from samples that had been stored in an archive plate (see Materials and Methods). The secondary pools were prepared by the Multiprep method and tested by the COBAS AmpliScreen HIV-1 test, v1.5. For those secondary pools that tested positive, all six individual samples in that pool were prepared by the Standard method and tested by the COBAS AmpliScreen HIV-1 test, v1.5, to identify the positive sample.
Each operator correctly identified the 10 positive and 10 negative primary pools (Table 6 ). For the 4 secondary pools of each of the 10 primary pools, the 1 secondary pool that contained the positive sample tested positive, while the other 3 secondary pools tested negative (Table 6 ). For each secondary pool, the positive sample was correctly identified, while the remaining 5 tested negative (Table 6 ). In aggregate, 90 tests performed on pools or samples known to be positive yielded positive results, and 270 tests performed on pools and samples known to be negative yielded negative results; no false-positive or false-negative test results were obtained. The lowand high-titer HIV-1 RNA-positive samples yielded similar HIV-1 signals when tested individually and when tested as a member of a primary or secondary pool.
DISCUSSION
The COBAS AmpliScreen HIV-1 test, v1.5, exhibited an analytical sensitivity of approximately 25 copies of HIV-1 RNA per mL of plasma for samples processed by the Multiprep method. Thus, this test should exhibit sufficient sensitivity for screening blood pools composed of 24 individual units. A single unit from an infected individual containing as little as 600 copies per mL will produce a final concentration of 25 copies per mL when pooled with 23 negative units. Published reports indicate that HIV-1 viral levels at * Number of days from the first positive p24Ag or COBAS AmpliScreen result to the first positive anti-HIV result, which occurred on the day shown in column 2 (where Day 0 is the day of collection for the first sample to look for seroconversion). † The day of collection of the first sample that gave a signal:cutoff ratio >1.0 in a licensed anti-HIV-1 test. ‡ Undiluted samples were tested by the Standard method and samples diluted 1-in-24 in HIV-1-negative plasma were tested by the Multiprep method. Samples that gave an HIV-1-specific signal A 660 >0.2 were scored as positive. § All samples in these panels tested negative for anti-HIV-1. The day the last sample was collected is shown, as by this point seroconversion had not occurred. || The sample collected on Day 0 tested positive.
¶ The first positive result was obtained on Day 28. seroconversion range from 10 3 to 10 7 genome equivalents per mL of plasma. [10] [11] [12] [13] A recent report concludes that, to shorten the window period more than can be achieved by p24Ag testing, NAT needs to detect an individual plasma sample containing 5000 copies per mL when it is diluted in a pool.
14 By detecting a single unit containing as few as 600 copies per mL in a pool of 24 units, the COBAS AmpliScreen HIV-1 test, v1.5, should reduce the preseroconversion window period substantially and should identify most nonseroconverting, chronically infected persons.
The results obtained for the seroconversion panels support these arguments. The COBAS AmpliScreen HIV-1 test, v1.5, detected HIV-1 RNA in plasma 2 to 14 days before anti-HIV seroconversion in all 10 panels tested. All samples in the seroconversion panels were diluted 1-in-24 with HIV-1-negative plasma to mimic the effect of pooling and then were processed by the Multiprep method. Thus, these data predict that the window phase will be reduced by 2 to 14 days during routine screening for a pool size of 24. It is important that the COBAS AmpliScreen test, v1.5, performed on diluted samples detected the presence of HIV-1 from 2 to 28 days earlier than a licensed p24Ag test performed on undiluted samples. These data are consistent with other observations suggesting that nucleic acid-based tests should reduce the 22-day window period by 10 to 15 days and should detect HIV-1 infection 3 to 8 days earlier than p24Ag testing. 14 The data presented here also suggest that infections will not be missed because of genetic variation within HIV-1 group M. The test does not, however, detect HIV-1 group O or HIV-2 infections. The test exhibited similar limits of detection (30-75 viral particles/mL) for 26 of 30 strains representing all HIV-1 group M genotypes; the only exceptions were four of the eight group E subtype strains, for which the limit of detection was 100 to 200 viral particles per mL. Theoretically, 1 particle corresponds to 2 copies of viral RNA. Thus, the test appeared to be one-half to one-sixth as sensitive in this set of experiments as in experiments performed with the NIBSC standard. The precision and accuracy of viral particle counts, however, are uncertain. Nor has the exact correspondence between viral particles and viral RNA as measured by quantitative tests been established. Even if the higher limits of detection are correct, the test will have sufficient sensitivity to substantially reduce the window period.
The Multiprep sample-processing method used in the COBAS AmpliScreen HIV-1 test, v1.5, incorporates an ultracentrifugation step to concentrate viral particles from plasma. HIV-1, HBV, and HCV are simultaneously recovered with efficiencies of 98 percent, 59 percent, and 23 to 45 percent, respectively. 8 The resulting fivefold increase in sample volume tested, combined with the efficiencies of virus recovery, enhances assay sensitivity 5-, 3-, and 1.5-fold for HIV-1, HBV, and HCV, respectively. 8 The ability to recover all three viruses by a single specimen-processing procedure provides an important practical advantage, as specimen processing is the most labor-intensive step of the COBAS AmpliScreen assay. By extracting the nucleic acid from the three most critical blood-borne pathogens in a single processed specimen, the laboratory can achieve the high throughput required for screening larger numbers of donated blood units, while reducing the cost of testing.
When a positive pool is detected during routine screening, it will be necessary to identify which unit within the pool is from an infected person. By constructing pools of known composition, we demonstrated that the COBAS AmpliScreen test, v1.5, not only accurately detected pools containing a positive unit, but also correctly identified the infected unit within the pool. Identification was achieved in a stepwise fashion by testing secondary pools containing 6 units and then testing the 6 individual units from the positive secondary pool. Like primary pools, secondary pools were prepared by the Multiprep method. Individual samples, however, were tested by the Standard processing method, which omits the centrifugation step. The Standard method was employed for individual samples, because it was not necessary to concentrate viral particles to compensate for the dilution effect of pooling.
The limit of detection for the Standard method was 100 copies of HIV-1 RNA per mL, which is approximately four to five times that obtained with the Multiprep method. This is consistent with the 5-fold difference in the volume of plasma introduced into the amplification reaction (250 µL and 50 µL for the Multiprep and Standard methods, respectively). Given these sample volumes, the limit of detection for both methods corresponds to approximately 6 copies of HIV-1 RNA molecules per amplification reaction. This approaches the lowest quantity of material that can be reproducibly detected. Poisson distribution statistics predict that 5 percent of reactions will give negative results, because of fluctuations in the number of target molecules delivered, when the average target concentration is 3 copies per amplification reaction, or where p(0) is the probability of having no molecules in a particular sample. Thus, the only way of reducing the limit of detection is to further concentrate the sample.
The COBAS AmpliScreen HIV-1 test, v1.5, did not react with other blood-borne viruses or plasma from 1013 seronegative individuals. When used to test known positive and negative pools and identify the individual positive units, the test did not generate any false-positive results among 270 tests performed on negative samples (see Table  6 ). Furthermore, AmpErase in the HIV-1, v1.5, Master Mix destroys any previously amplified, deoxyuridine-containing DNA, protecting against false-positive results due to carryover contamination. Thus, a positive result is specific for HIV-1. High specificity is critical for achieving a high positive predictive value, which minimizes the cost of p(0) = e -3 = 0.05 screening. False-positive results will result in costly retesting to identify the infected unit in the pool and could cause some plasma pools to be unnecessarily rejected. Elevated levels of normal blood substances did not interfere with the COBAS AmpliScreen HIV-1 test, v1.5. Nevertheless, the IC included in the AmpliScreen test is crucial for achieving the high negative predictive value required to exclude infected units from the blood supply. The IC is introduced into each pool at the lysis step and is processed and amplified along with any target nucleic acid in the pool. A negative IC result indicates that results for the specific target may be falsely negative because of amplification inhibitors or improper specimen processing. 15 In contrast, a positive IC result combined with a negative result for the specific target excludes test failure, which implies that the specific target is either absent or present at a concentration below 80 copies per mL of plasma (corresponds to 20 copies/reaction, which is equivalent to the IC concentration).
In summary, the COBAS AmpliScreen HIV-1 test, v1.5, provides a semi-automated, sensitive, and specific method for screening pooled blood units for HIV-1. The test has sufficient sensitivity to detect a single infected preseroconversion unit in a pool of 24 units and incorporates an IC to ensure the validity of negative results. The Multiprep specimen-processing method used in the test also recovers HCV and HBV nucleic acids with high efficiency, which allows laboratories to extract all three blood-borne pathogens in a single processed sample.
